Odyssey Therapeutics, Inc. - 8-K Filing

Odyssey Therapeutics presented completed Phase 2a OD-001 induction results showing strong clinical proof of concept at UEG Week 2026. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $ODTX

Read the full article at SEC EDGAR

More Regulatory news